Avalyn Pharma Inc. 10-Q filing
Filed 2026-06-03 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-254623
- Form type
- 10-Q
- CIK
- 0001540171
- Primary document
- https://www.sec.gov/Archives/edgar/data/1540171/000119312526254623/ck0001540171-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Avalyn Pharma Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-27.9M | - | - |
| Net Income | $-26.9M | - | - |
| Eps Basic | -21.83 | - | - |
| Eps Diluted | -21.83 | - | - |
| Cash And Equivalents | $92.3M | - | - |
| Total Assets | $135.7M | - | - |
| Total Liabilities | $27.7M | - | - |
| Shareholders Equity | $-264.2M | - | - |
| Operating Cash Flow | $-29.9M | - | - |
| Capital Expenditures | $318,000 | - | - |